TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xbrane Biopharma AB ( (SE:XBRANE) ) just unveiled an announcement.
Xbrane Biopharma AB announced a teleconference for investors, analysts, and media to discuss its interim report for January to June 2025, scheduled for August 26, 2025. The report will be presented by CEO Martin Åmark and CFO Jane Benyamin, followed by a Q&A session. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (SE:XBRANE) stock is a Hold with a SEK0.50 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a company that develops biological drugs using a patented platform technology, which allows for significantly lower production costs compared to other systems. The company focuses on biosimilar candidates with a target market of EUR 23 billion in estimated annual peak sales. Xbrane’s lead candidate, Ximluci®, has received market authorization in Europe and was launched in 2023. The company is headquartered in Solna, Sweden, and is listed on Nasdaq Stockholm.
Average Trading Volume: 14,915,653
Technical Sentiment Signal: Sell
Current Market Cap: SEK437M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.